


IN THE CLAIMS

Please amend the claims as follows:

1. (Twice Amended) A compound which is an antagonist of a G protein-coupled receptor, which has no agonist activity, and which has a cyclic or constrained acyclic structure adapted to provide a framework of approximate dimensions as set out in Structure I:

Structure I




where the numerals refer to distances between  $C_{\alpha}$  carbons of amino acids or their analogues or derivatives, and A, B, C and D are not necessarily on adjacent amino acids, or analogues or derivatives thereof; and

where the critical amino acid side chains are designated by A, B, C and D, where  
A is any common or uncommon, basic, charged amino acid side chain which serves to position a positively charged group in this position;

B is any common or uncommon, aromatic amino acid side chain which serves to position an aromatic side-chain in this position;

*E1*  
C is any common or uncommon, hydrophobic amino acid side chain which serves to position any alkyl, aromatic or other group in this position;

*D* is any common or uncommon, aromatic amino acid which serves to position an aromatic side-chain in this position, and has the structure:



where  $Z$  is indole, indole methyl, benzyl, benzene, naphthyl, naphthyl methyl, or a derivative thereof; and

$\text{R}^1$  is H or an alkyl, aromatic, acyl or aromatic-acyl group.

*E2*  
5. (Twice Amended) An antagonist according to Claim 1, which is a constrained acyclic compound, comprising a type II  $\beta$ -turn.

*E3*  
8. (Twice Amended) An antagonist according to Claim 1, of formula  
Ac-Phe-[Lys-Pro-(dCha)-Trp-Arg] or  
Ac-Phe-[Orn-Pro-(dCha)-Trp-Arg].

*E4*  
13. (Twice Amended) An antagonist according to Claim 10, selected from the group consisting of AcF-[KpdChaWR], AcF-[OPdChaWR], F-[XPdChaWR], F-[XPdChaWR], F-[ $X^2$ PdChaWR], F-[ $X^2$ PdChaWR], AcF-[OPdChaWR], AcF-[OPdChaWR], [FWPdChaWR], AcF-[KMdChaWR], AcF-[KKdChaWR], AcF-[XPdChaWR], AcF-[ $X^2$ PdChaWR], AcKF-[OPdChaWR], F-[OPdChaWR], F-[KPdChaWR], F-[OPdChaWR] and F-[KPdChaWR], wherein X is  $(\text{CH}_2)\text{-NH}_2$  and  $X^2$  is  $(\text{CH}_2)_2\text{-NH}_2$ .

14. (Twice Amended) An antagonist according to Claim 10, in which n is 2 or 3.

*E5*  
21. (Twice Amended) A method of treatment of a pathological condition mediated by a G - protein-coupled receptor, comprising the step of administering an effective amount of a